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IFN-/ NOD.H-2h4 mice develop an autoimmune
disease characterized by hyperplasia and prolifera-
tion of thyroid epithelial cells (TEC H/P). Proliferating
TECs produce TGF-, and IFN- inhibits TEC H/P. In
the present study, cultured TECs were used to directly
determine the mechanisms by which these cytokines
act on TECs to result in proliferation or inhibition of
proliferation. With TECs from IFN-/ NOD.H-2h4
mice or mice expressing the dominant negative TGF-
type II receptor on TECs, TGF- was shown to pro-
mote TEC proliferation and IFN- was shown to in-
hibit TEC proliferation in vitro. TGF- may promote
TEC proliferation by down-regulating antiprolifera-
tive molecules p21 and p27, whereas IFN- may in-
hibit proliferation by up-regulating antiproliferative
molecules p18 and p21 and down-regulating the pro-
proliferative molecule cyclin D. Inhibition of AKT
abolished the effect of TGF- on p21 and p27, result-
ing in similar proliferation of TGF--treated and con-
trol TECs. Increased expression of proliferating cell
nuclear antigen (PCNA), TGF-, and p-AKT and de-
creased expression of p21 and p27 by proliferating
TECs correlated with the proliferative state of TEC
H/P. Taken together, the results suggest that TGF-
promotes TEC proliferation by down-regulating p21
and p27 via the AKT pathway in IFN-/ NOD.H-2h4
mice, which may have significant implications for
development of effective therapeutic strategies target-
ing the TGF- and AKT pathways for treatment of
hyperplasia and/or neoplasia. (Am J Pathol 2012, 180:
650–660; DOI: 10.1016/j.ajpath.2011.10.009)
TGF- is a multifunctional cytokine with diverse biological
effects on many cellular processes, including cell prolif-
650eration.1–3 TGF- exerts its functions through a cell sur-
face receptor complex composed of type I (TGFBR1) and
type II (TGFBR2) serine/threonine kinase receptors. The
Smad pathway is a well-studied pathway used for TGF-
signaling, but TGF- also uses other intracellular signal-
ing pathways to regulate various cellular functions, in-
cluding proliferation,1,4 which at least in part explains its
functional versatility. TGF- can promote cell proliferation
in many tumor cells,2,3,5,6 but it also has antiproliferative
effects on some cells, including epithelial cells.7,8 Con-
siderable progress has been made toward understand-
ing the signaling networks and downstream pathways
after the binding of TGF- with its receptors. Increasing
evidence suggests that co-operation between Smad and
non-Smad signaling pathways determines the final out-
come of the cellular response to TGF-.1,4 The nonca-
nonical, non-Smad pathways are activated directly by
ligand-occupied receptors to reinforce, attenuate, or oth-
erwise modulate downstream cellular responses. The
AKT pathway is one non-Smad pathway4 that has been
shown to be crucial for a number of cellular responses to
growth factors, including cell proliferation.9 It has been
suggested that the signal transduced by TGF- binding
to its receptors depends on the cell type and the sur-
rounding hormone/growth factor context.10,11
IFN- is another multifunctional cytokine that plays an
important role in many autoimmune diseases, including
thyroiditis. IFN- is the prototypic Th1 cytokine produced
by CD4 Th1 cells, CD8 T cells, and natural killer
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other,14,15 and so regulate cell proliferation.
The eukaryotic cell cycle is tightly regulated to ensure
that replication and division take place in a controlled
manner.16–19 The balance between pro- and antiprolif-
erative molecules plays an important role in cell prolifer-
ation. Cyclin D, cyclin E, and cyclin-dependent kinases
are important pro-proliferative molecules. Down-regula-
tion of cyclin D can delay or inhibit entry to the S phase of
the cell cycle, and overexpression of cyclin D can shorten
the G1 phase.16–19 Cyclin E is active in the late G1 phase
and is maximal at the G1-to-S transition. p21, p27, p18,
and p53, as well as p15, p16, p19, and p57, are impor-
tant antiproliferative molecules that function to inhibit cy-
clin-dependent kinases and thus have antiproliferative
effects.16–19
Autoimmune thyroid diseases are often associated
with abnormal proliferation (hyperplasia) of thyroid epi-
thelial cells (TECs). Thyroid hyperplasia is very common
and can be associated with development of goiter, thy-
roid adenoma, and carcinoma.20 We previously showed
that IFN-/ NOD.H-2h4 mice develop an autoimmune
disease characterized by severe TEC hyperplasia and
proliferation (TEC H/P) and development of fibrosis.21
TEC proliferation is promoted by TGF-, which is pro-
duced by the proliferating TECs.21 IFN- produced by T
cells inhibits TEC proliferation in this model, presumably
by acting directly on TECs.22 These in vivo studies pro-
vide indirect evidence suggesting that TGF- acts di-
rectly on TECs to promote their proliferation, whereas
IFN- suppresses TEC proliferation by interfering with the
effects of TGF-.21,22 The present study was conducted
to extend these in vivo studies by using an in vitro system
in which the interactions of cytokines with TECs could be
controlled to directly define the mechanisms by which
IFN- and TGF- interact with TECs to inhibit or promote
their proliferation.
Materials and Methods
Mice
NOD.H-2h4 mice express H-2Kk, I-Ak, and Dd on the
NOD background.23 NOD.H-2h4 wild-type, IFN-/,
IFN-R/, and IFN-/-SCID mice were generated in
our animal facility as described previously.22 To generate
transgenic mice expressing the dominant negative
TGF- type II receptor (dnTRII) on TECs, we used a
plasmid containing the recombinant dnTRII construct
tagged with FLAG (kindly provided by Dr. H. Moses,
Vanderbilt University). This construct was combined with
the rat thyroglobulin (TG) promoter (with the assistance of
Dr. J. Qiu, University of Kansas Medical Center), ampli-
fied in Escherichia coli, and digested using SalI and XbaI
(Invitrogen, Carlsbad, CA). The 1.652K-bp recombined
construct was microinjected into fertilized oocytes from
NOD.H-2h4 female mice at the Transgenic Core Facility
of the University of Missouri, Columbia. Transgenic
founders were screened by PCR of tail DNA using the
following primers: sense, 5=-GGAGCCAGGGCTGGGC-ATAAAA-3=; antisense, 5=-GACTCACCCTGAAGTTCTC-
AGGATCC-3=. A transgenic female founder was crossed
with a NOD.H-2h4 IFN-/ male, and Tg offspring
were further crossed to obtain Tg IFN-/ mice. Tg
mice and Tg IFN-/ littermates were used for all ex-
periments. Mice were bred and maintained in accor-
dance with University of Missouri institutional guidelines
for animal care.
Western Blot
Expression of TRII and FLAG was quantified by Western
blot analysis with rabbit anti-TRII (Santa Cruz Biotech-
nology, Santa Cruz, CA) and anti-FLAG (Abcam, Cam-
bridge, MA) by adding 30 g of protein to a 15% SDS-
PAGE gel as described previously.24 Expression of p21
and p27 was quantified using rabbit anti-p21 and anti-
p27 antibodies (Santa Cruz Biotechnology) by adding 30
g of protein to a 15% SDS-PAGE gel.24 For normaliza-
tion of signals, the membranes were stripped and re-
probed with 1/2000 rabbit anti-actin primary antibody
(Santa Cruz Biotechnology) and 1/3000 HRP-conjugated
anti-rabbit IgG as secondary antibody, as described pre-
viously.24
Real-Time PCR
Individual thyroid lobes were homogenized in TRIzol re-
agent (Invitrogen). RNA was extracted and 1 g RNA
was reverse transcribed as described previously.25,26
TRII mRNA was quantified by real-time PCR using an
ABI 7000 sequence detection system (Applied Biosys-
tems, Foster City, CA). Amplification was performed for
40 cycles in a total volume of 30 L; products were
detected using SYBR Green (Thermo Scientific; ABgene,
Epsom, UK). The relative expression levels of triplicate
samples were determined by normalizing expression of
each target to HPRT. Expression level of each normalized
sample is given as relative expression units. Real-time
PCR primers for TRII were as follows: sense, 5=-AGCAT-
CACGGCCATCTGTG-3=; antisense, 5=-TGGCAAACCG-
TCTCCAGAGT-3=. The size of the amplified product for
TRII is 166 bp.
Immunohistochemistry
IHC staining for TRII, FLAG, PCNA, p-AKT, TGF-, p21,
and p27 was performed as described previously.27 Thy-
roid sections were deparaffinized in xylene, rehydrated
through sequential ethanol, and rinsed in PBS. Sections
were incubated with rabbit anti-TRII, anti-FLAG, anti-
PCNA, anti-p-AKT, anti-p21, and anti-p27 (Santa Cruz
Biotechnology) and chicken anti-TGF- antibodies (R&D
Systems, Minneapolis, MN) for 60 minutes at room tem-
perature. After incubation with the corresponding sec-
ondary biotinylated antibody (Jackson ImmunoResearch,
West Grove, PA), immunoreactivity was demonstrated
using the avidin-biotin complex immunoperoxidase sys-
tem (Vector Laboratories, Burlingame, CA) and devel-
oped using Vector NovaRED as the chromogen. Slides
were counterstained with hematoxylin. As a negative con-
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of normal rabbit or chicken IgG; these controls were
always negative.
Primary Culture of TECs from IFN-/
NOD.H-2h4 Mice
Mouse primary TEC cultures were generated as de-
scribed previously.28 In brief, thyroid lobes from groups
of six 8- to 10-week-old naïve IFN-/ NOD.H-2h4 mice
or from dnTRII Tg littermates were aseptically dis-
sected, disrupted, and digested for 1 hour at 37°C in
digestion medium consisting of 112 units/mL of type I
collagenase and 1.2 units/mL of dispase II dissolved in
Eagle’s minimal essential medium. After centrifugation,
pellets were resuspended in 15 mL of TEC culture me-
dium, seeded in eight-well chamber slides (0.2 to 0.3
mL/well; Nalge Nunc International, Naperville, IL), and
cultured at 37°C. When cultures reached 70% to 80%
confluence, usually after 2 to 3 weeks, cultured TECs
were treated for 3 days with different concentrations of
IFN- (2 to 20 ng/mL; eBioscience, San Diego, CA), acid-
activated TGF- (0.1 to 2 ng/mL; PeproTech, Rocky Hill,
NJ), or medium alone. IFN- and TGF- concentrations
and the duration of cytokine treatment were based on our
previous studies28 and those of others.11
Determination of Proliferation of Cultured TECs
Proliferation of cultured TECs was determined by prolif-
eration marker PCNA staining by IHC as described pre-
viously.21 NovaRED (Vector Laboratories) was used for
color development, and slides were counterstained with
hematoxylin. To quantify the number of proliferating
TECs, all cells in five to six randomly selected high-power
fields (400 magnification) were manually counted using
MetaMorph version 6.3r6 image analysis software (Mo-
lecular Devices Analytical Technologies, Sunnyvale, CA)
as described previously.29 PCNA cells were expressed
as a percentage of total cells. In some experiments, pro-
liferation was determined using a Quick Cell proliferation
assay kit (BioVision, Mountain View, CA) according to the
manufacturer’s instructions.30
TUNEL Staining
Apoptosis of cultured TECs was determined by TUNEL
assay using an ApopTag kit (Millipore; Chemicon Inter-
national, Temecula, CA) as described previously.28 TECs
treated with resveratrol were used as a positive control for
apoptosis.
RT-PCR
Cultured TECs were harvested, washed with PBS, centri-
fuged, and homogenized in TRIzol reagent (Invitrogen).
RNA was extracted and 1 g RNA was reverse tran-
scribed as described previously.25,27 -Actin was used
as a housekeeping gene to verify that the same amount of
RNA was amplified. Primer sequences were as follows:PCNA sense, 5=-GGTTGGTAGTTGTCGGTGTA-3= and
antisense, 5=-CAGGCTCATTCATCTCTATCG-3=; p21 sense,
5=-AGCCTGAAGACTGTGATGGG-3= and antisense, 5=-
AAAGTTCCACCGTTCTCGG-3=; p27 sense, 5=-AAGCACT-
GCCGGGATATGGA-3= and antisense, 5=-AACCCAGCCT-
GATTGTCTGAC-3=; p18 sense, 5=-AGATTAACCATCC-
CAGTCCT-3= and antisense, 5=-CTGAATGGGTGGATT-
AGGTA-3=; p53 sense, 5=-ACTGCATGGACGATCTGT-
TG-3= and antisense, 5=-GCCATAGTTGCCCTGCTAAG-3=;
and cyclin D sense, 5=-TCTACACTGACAACTCTATCCG-3=
and antisense, 5=-TAGCAGGAGAGGAAGTTGTTGG-3=.
Treatment of Cultured TECs with AKT Inhibitor
Cultured TECs, 70% to 80% confluent, were treated with an
AKT inhibitor (AKT1/2 kinase inhibitor, 30 mol/L; Sigma-
Aldrich, St. Louis, MO) for 3 days with TGF- (2 ng/mL) or
medium alone. Cells were analyzed by IHC for PCNA and
by RT-PCR for mRNA expression.
Induction of TEC H/P in Vivo
Splenocytes from IFN-/ mice with severe TEC H/P
and fibrosis were pooled and cultured for 72 hours in
complete RPMI 1640 medium as described previously.31
Splenocytes (3 106) were transferred intravenously into
NOD.H-2h4 IFN-/ SCID mice. Mice were given 0.05%
NaI water, and thyroid histology was assessed 28 days
and either 35 or 60 days later.
Evaluation of TEC H/P Severity
Thyroids were removed, and one thyroid lobe was fixed in
formalin, sectioned, and stained with H&E as described
previously.31,32 All slides were scored by two individuals
(H.B.-M. and Y.F. or S.Y.), one of whom had no knowl-
edge of the experimental groups (Y.F. or S.Y.). Thyroid
histopathology was scored for the extent of thyroid follic-
ular cell hyperplasia/proliferation, using a scale of 0 to
5, as described previously.31,32 Briefly, a score of 0
indicates a normal thyroid, and 0 indicates mild follic-
ular changes and/or a few inflammatory cells infiltrating
the thyroids. A 1 score indicates hyperplastic changes
sufficient to cause replacement of several follicles. A 2
score indicates hyperplastic changes causing replace-
ment or destruction of up to 1/4 of the gland, 3 indicates
that 1/4 to 1/2 of the gland is destroyed by hyperplastic
changes, and 4 indicates that greater than 1/2 of the
gland is destroyed. Thyroids given a score of 5 had few
or no remaining normal follicles and extensive collagen
deposition (fibrosis). The severe lesions in IFN-/ mice
(graded 4 to 5, based on the percentage of normal
thyroid follicles remaining) had widespread clusters of
proliferating TECs and histiocytes with some lymphocyte
infiltration. The areas of proliferating TECs were usually
surrounded by collagen. All thyroids with mild or severe
hyperplasia had infiltrating lymphocytes, but lymphocyte
infiltration was much less than in thyroids of wild-type
mice with spontaneous autoimmune thyroiditis.
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All experiments were repeated two or three times. Statis-
tical analysis of data were performed using an unpaired
two-tailed Student’s t-test or the Mann-Whitney rank-sum
test. A P value of 0.05 was considered significant.
Results
Generation of dnTRII Transgenic Mice and
Expression of dnTRII and FLAG on TECs
Our previous studies indicated that overexpression of
TGF- on TECs promotes development of TEC H/P in
vivo.21 To directly test the hypothesis that TGF- pro-
motes TEC proliferation in vitro and to determine possible
mechanisms, dnTRII transgenic mice were generated
as described under Materials and Methods (see Supple-
mental Figure S1A at http://ajp.amjpathol.org). Western
blot, real-time PCR, and IHC analyses showed that TRII
was constitutively expressed on TECs in Tg littermates
and that TRII was significantly overexpressed on TECs
in Tg mice (see Supplemental Figure S1, B–D, at http://
ajp.amjpathol.org). Transgenic TRII (detected by anti-
FLAG) was expressed in TECs (see Supplemental Figure
S1, B and D, at http://ajp.amjpathol.org), but not in other
tissues (including spleen, liver, salivary gland, and cer-
vical lymph nodes; data not shown). Western blot analy-
sis and real-time PCR indicated that the dnTRII levels in
naïve Tg mice were five- to sixfold higher, compared
with expression of the endogenous receptor in Tg litter-
mates (see Supplemental Figure S1, B and C, at http://
ajp.amjpathol.org).
TGF- Promotes Proliferation of Cultured TECs
from IFN-/ Tg Mice but Not dnTRII Tg
Mice
To directly determine whether TGF- promotes prolifera-
tion of TECs in vitro, primary cultures of TECs from
dnTRII Tg IFN-/ NOD.H-2h4 mice and their Tg
littermates were established, and various concentrations
of TGF- were added for 72 hours. Assessment of prolif-
eration by PCNA staining (Figure 1, A and C) indicated
that TGF- promotes proliferation of TECs from nontrans-
genic IFN-/mice in vitro in a dose-dependent manner,
but has no effect on TECs of dnTRII Tg mice. Similar
results were also obtained with a cell proliferation assay
(Figure 2A) and by mRNA analysis for PCNA (Figure 3A).
These results indicate that TGF- directly promotes pro-
liferation of cultured TECs by binding with its receptor.
IFN- Inhibits Proliferation of Cultured TECs from
IFN-/ but Not IFN-R/ NOD.H-2h4 Mice
Our previous studies showed that TEC H/P develops only
in mice that lack IFN- or in mice whose TECs cannot
respond to IFN- (IFN-R/ mice).22 IFN--sufficient
NOD.H-2h4 mice do not develop TEC H/P, and wild-type
splenocytes able to produce IFN- suppress TEC H/P inIFN-/ but not in IFN-R/ NOD.H-2h4 mice.22 This
suggests that IFN- can directly suppress TEC prolifera-
tion in vitro. To address this possibility, primary cultures of
TECs from naïve IFN-/ and IFN-R / NOD.H-2h4
mice were established, and various concentrations of IFN-
were added for 3 days. Assessment of proliferation by
PCNA staining indicated that IFN- inhibits proliferation of
TECs from IFN-/ NOD.H-2h4 mice in a dose-dependent
manner in vitro, but has no effect on TECs from IFN-R/
NOD.H-2h4 mice (Figure 1, A and C). Similar results were
obtained with a cell proliferation assay for TEC proliferation
(Figure 2B) and by mRNA analysis for PCNA (Figure 4A).
Consistent with our earlier in vivo results,21 these in vitro
results directly demonstrate that TGF- promotes and IFN-
inhibits proliferation of cultured TECs.
TGF- Promotes Proliferation of Cultured TECs
by Modulating Antiproliferative Molecules
The balance between pro- and antiproliferative mole-
cules plays an important role in cell proliferation.16–19
Cyclin D and cyclin E are important pro-proliferative
molecules, and p21, p27, p18, and p53 are important
antiproliferative molecules.16–19 To determine whether
pro- and antiproliferative molecules are involved in TGF-
-induced proliferation of TECs, mRNA expression of
pro- and antiproliferative molecules in cultured TECs from
dnTRII Tg mice and their Tg littermates in the pres-
ence or absence of TGF- was determined by RT-PCR.
Consistent with the IHC and cell proliferation assay find-
ings for TGF- and IFN- (Figures 1 and 2), mRNA ex-
pression of PCNA was increased in TECs from nontrans-
genic mice after culture with TGF-, but TGF- had no
effect on PCNA expression in TECs from dnTRII Tg
mice (Figure 3A). Of particular interest, mRNA expression
of the antiproliferative molecules p21 and p27 was sig-
nificantly lower in TECs from Tg mice when TGF- was
added to the culture, but expression of these molecules
by TECs of dnTRII Tgmice was unaffected by addition
of TGF- (Figure 3, B and C). mRNA expression of other
antiproliferative molecules such as p18 (Figure 3D) or p53
(data not shown), as well as mRNA expression of the pro-
proliferative molecules cyclin D (Figure 3E) and cyclin E
(data not shown), was unaffected by addition of TGF- to
TECs of Tg or Tg mice. Western blot analysis further
confirmed that p21 levels in TECs from Tg mice were
decreased in the presence of TGF- (Figure 3F). Given that
expression of all of these markers was unaffected in TECs
from dnTRII Tg mice, the results suggest that down-
regulation of the antiproliferative molecules p21 and p27 is
associated with TGF--induced proliferation of TECs.
IFN- Inhibits Proliferation of Cultured TECs by
Modulating Pro- and Antiproliferative Molecules
To determine whether pro- and antiproliferative mole-
cules are involved in IFN--inhibited proliferation of TECs,
mRNA expression of major pro- and antiproliferative mol-
ecules in cultured TECs from IFN-/ and IFN-R/NOD.H-2h4 mice was determined by RT-PCR. Consistent
prolifer
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TGF- and IFN- (Figures 1 and 2), PCNA mRNA was
significantly lower in TECs from IFN-/ NOD.H-2h4
mice in the presence of IFN-. Expression of mRNA of the
antiproliferative molecules p21 and p18 was significantly
higher and that of the pro-proliferative molecule cyclin D
was significantly lower in TECs from IFN-/ NOD.H-2h4
mice in the presence of IFN- (Figure 4). Expression of
the antiproliferative molecules p27 (Figure 4) and p53
(data not shown) or the pro-proliferative molecule cyclin E
(data not shown) was unaffected by IFN-, and expres-
Figure 1. Effect of TGF- and IFN- on TEC proliferation evaluated by IHC
Tg and Tg (dnTRII) mice cultured with the indicated amounts of TGF-
with the indicated amounts of IFN- (B). Original magnification, 400. C a
wells/group were counted using MetaMorph software. Summarized results a
mice but not from Tg mice (*P  0.05), and 6 or 20 ng/mL IFN- inhibited
IFN-R/ mice. The activity of IFN- is 5 U/ng.sion of all markers was unaffected in IFN-R/ TECsunable to respond to IFN-. These results indicate that
up-regulation of the antiproliferative molecules p21 and
p18 and down-regulation of the pro-proliferative molecule
cyclin D are associated with IFN--mediated inhibition of
TEC proliferation.
TGF- and IFN- Have Little Effect on TEC
Apoptosis
Changes in apoptosis could contribute to the TGF--
are IHC staining results for PCNA of cultured TECs from IFN-/ (GKO)
results for PCNA of cultured TECs from GKO and IFN-R/ mice cultured
NA cells (red) in five to six randomly selected high-power fields of three
n; 0.5 or 2 ng/mL TGF- induced significant proliferation of TECs from Tg
ation of TECs from IFN-/ mice (P  0.05) but had no effect on TECs of. Shown
(A) and
nd D: PC
re showinduced or IFN--inhibited proliferation of TECs. To ad-
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80% confluent cultured TECs from dnTRII Tgmice and
their Tg littermates were treated with or without TGF- (2
ng/mL) and TECs from IFN-/ NOD.H-2h4 mice were
treated with IFN- (20 ng/mL) for 3 days. Apoptosis was
detected by TUNEL staining. Few or no TUNEL-positive
cells were detected in TECs cultured in the presence or
absence of cytokines (data not shown), suggesting that
apoptosis is not involved in the process of TGF--in-
duced or IFN--inhibited proliferation of TECs.
Figure 2. Effect of TGF- and IFN- on TEC proliferation determined using
a proliferation kit. A: TGF- promotes proliferation of cultured TECs from
GKO Tg mice but not from GKO Tg mice. B: IFN- inhibits proliferation
of cultured TECs from GKO but not from IFN-R/ mice. Results are
expressed as the mean optical density (OD)  SEM of TECs from four to five
wells/group and are representative of three independent experiments.
*P  0.05 versus medium (M) alone.
Figure 3. Effect of TGF- on pro- and antiproliferativemolecules in cultured TECs.
mRNA and proteinswere extracted as described underMaterials andMethods.A–E:
RT-PCR. F:Western blot. Results are expressed as themean ratio of PCNA, pro- and
antiproliferative molecule densitometric units/-actin  SEM (100) and are
representative of two to three independent experiments. *P  0.05 versus
medium (M) alone.TGF--Induced Proliferation of TECs Is
Associated with Increased p-AKT
TGF- makes use of several intracellular signaling path-
ways, in addition to the Smad pathway, to regulate cel-
lular functions.1,4 The AKT pathway has been shown to
be important for cell proliferation and other responses to
growth factors,9 so it was of interest to determine whether
the AKT pathway is involved in TGF--induced prolifera-
tion of TECs. To address this question, primary cultures of
TECs from dnTRII Tg IFN-/ mice and their Tg
littermates were established, and TGF- was added for 3
days. TGF- induced p-AKT expression in TECs of Tg
mice, but not in TECs of dnTRII Tg mice (Figure 5, A
and B). Western blot analysis further confirmed that p-
AKT was increased in TECs from Tg mice in the pres-
ence of TGF- (Figure 6A). These results suggest that
TGF--induced proliferation of TECs is associated with
increased p-AKT.
AKT Inhibitor Inhibits TGF--Induced
Proliferation of TECs
To further confirm the involvement of the AKT pathway in
TGF--induced proliferation of TECs, an AKT inhibitor
was used to attempt to block TGF--induced proliferation
of TECs. Primary cultures of TECs from dnTRII Tgmice
and their Tg littermates were established, and TGF- or
Figure 4. IFN- inhibits proliferation of cultured TECs by modulating pro- and
antiproliferative molecules. RT-PCR results are expressed as the mean ratio of
PCNA, pro- and antiproliferative molecule densitometric units/-actin SEM
(100), and are representative of three independent experiments. *P  0.05
versus medium (M) alone.medium with or without AKT inhibitor was added for 3
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proliferation of TECs from Tg mice, but had little effect
on proliferation of TECs from dnTRII Tgmice (Figure 5,
A and C). Similar results were also obtained with a cell
proliferation assay (Figure 5D) and by mRNA analysis for
PCNA (Figure 6B). These results strongly indicate that
TGF--induced proliferation of TECs is through the AKT
pathway.
AKT Inhibitor Reverses the Effects of TGF- on
Antiproliferative Molecules
Because AKT inhibitor inhibits TGF--induced prolifera-
tion of TECs (Figure 5) and TGF--induced proliferation of
TECs is associated with down-regulation of the antipro-
liferative molecules p21 and p27 (Figure 3), it is important
to determine whether down-regulation of the antiprolifera-
tive molecules p21 and p27 is abrogated by the AKT
inhibitor. To address this question, TGF- with or without
AKT inhibitor was added to primary cultures of TECs for 3
days, and mRNA expression of p21, p27 and PCNA wasdetermined by RT-PCR. Consistent with the results de-
scribed above (Figure 5), PCNA mRNA in TECs was
significantly lower when both TGF- and AKT inhibitor
were added to the culture than when TGF- alone was
added (Figure 6B). Of particular interest, p21 and p27
mRNA was significantly higher in TECs cultured with
TGF- and AKT inhibitor, compared with TECs cultured
with TGF- alone (Figure 6, C and D). These results
indicate that AKT inhibition reverses the ability of TGF-
to down-regulate p21 and p27. Taken together, the re-
sults suggest that TGF- promotes proliferation of TECs
by down-regulation of p21 and p27 via the AKT pathway.
Increased Proliferation of TECs Correlates with
Increased Expression of TGF- and p-AKT and
Decreased Expression of p21 and p27 in TECs
in Vivo
To determine whether our in vitro findings suggesting that
Figure 5. TGF--induced proliferation of TECs
is associated with increased p-AKT, and AKT
inhibitor inhibits TGF--induced proliferation of
TECs. Primary cultures of TECs from dnTRII
Tg IFN-/ NOD.H-2h4 mice and their Tg
littermates were established, and TGF- (2 ng/
mL) was added for 3 days. A: IHC results for
p-AKT and PCNA. Primary cultures of TECs from
dnTRII Tg mice and their Tg littermates
were established, and TGF- (2 ng/mL) or me-
dium with or without AKT inhibitor (30 mol/L)
was added for 3 days. Original magnification:
100 (p-AKT); 400 (PCNA). B and C: p-AKT
or PCNA cells (red) in five to six randomly
selected high power fields of three wells/group
were counted using MetaMorph software. Sum-
marized results are shown. *P  0.05 versus
medium alone (B). *P  0.05 versus TGF-
alone (C). D: A cell proliferation kit was used to
evaluate the effect of AKT inhibitor on TGF--
induced proliferation of TECs. Results are ex-
pressed as the mean OD  SEM of TECs from
four to five wells/group. *P  0.05 versus TGF-
alone. Results are representative of two or three
independent experiments.TGF- promotes proliferation of TECs by down-regulation
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pression of these molecules in vivo, we used a well-es-
tablished murine model of TEC hyperplasia. IFN-/
NOD.H-2h4 mice develop severe TEC H/P and fibrosis,
whereas IFN-/ SCID mice do not develop TEC
H/P.31,32 Splenocytes from IFN-/ mice with severe
TEC H/P transfer severe TEC H/P to SCID recipients.31,32
At 28 days after cell transfer (Figure 7A), most recipients
had severe TEC H/P (severity score, 4 to 5) with
infiltration of thyroids by T cells, macrophages, and eo-
sinophils, extensive proliferation of TECs, and some fibro-
sis. By day 60 (Figure 7A), thyroids were larger and
there was more fibrosis and fewer infiltrating T cells,
macrophages, and eosinophils. There were also fewer
proliferating PCNA TECs, and proliferating TECs were
surrounded by collagen, resulting in severe nodular
hyperplasia (5 TEC H/P).
The similarity in TEC H/P severity scores but differ-
ences in proliferating status of TECs at day 28 versus day
60 provided a good opportunity to determine whether the
proliferation status of TECs correlates with expression of
TGF-, p-AKT, p21, and p27 in TECs in vivo. At day 28,
there were many PCNA TECs (Figure 7, A and B), and
they had strong staining for TGF- and p-AKT (Figure 7,
A and C), whereas the staining intensity for the antipro-
liferative molecules p21 and p27 was weaker (Figure 7, A
Figure 6. TGF--induced proliferation of TECs is associated with increased
p-AKT and AKT inhibitor reverses the ability of TGF- to down-regulate
antiproliferative molecules A:Western blot analysis. Results are expressed as
the mean ratio of p-AKT densitometric units/-actin  SEM (100). *P 
0.05 versus medium alone. B–D: Primary cultures of TECs from dnTRII Tg
mice and their Tg littermates were established. TGF- (2 ng/mL) with or
without AKT inhibitor (30 mol/L) was added for 3 days. mRNA expression
of p21, p27, and PCNA in cultured TECs from dnTRII Tg mice and their
Tg littermates was determined by RT-PCR. Results are expressed as the
mean ratio of PCNA, pro- and antiproliferative molecule densitometric units/
-actin  SEM (100), and are representative of three independent exper-
iments. Results are representative of two independent experiments. *P 0.05
versus TGF- alone.and B). In contrast, at day 60, although the TEC H/Pseverity scores were similar to those at day 28, there were
fewer PCNA TECs, the staining intensity for TGF- and
p-AKT in TECs was weaker, and the staining intensity for
p21 and p27 was very strong (Figure 7, A–D). p21 and
p27 were located both in the nucleus and the cytoplasm
in TECs. The higher expression level of p-AKT and the
lower expression levels of p21 and p27 at day 28, com-
pared with those at day 60, were also confirmed by
Western blot analysis (Figure 7E). Thus, increased prolif-
eration of TECs correlates with increased expression of
TGF- and p-AKT and decreased expression of p21 and
p27 in TECs in vivo.
Discussion
Regulation of thyroid growth and function is achieved by
the balance between pro- and antiproliferative mole-
cules.11,33,34 The present findings demonstrate that
TGF- promotes and IFN- inhibits TEC proliferation in a
dose-dependent manner in vitro. The findings suggest
that TGF- may promote TEC proliferation by down-reg-
ulating antiproliferative molecules p21 and p27, whereas
IFN- may inhibit proliferation by up-regulating antiprolif-
erative molecules p18 and p21 and down-regulating the
pro-proliferative molecule cyclin D. AKT inhibition abol-
ished the effect of TGF- on p21 and p27, resulting in
similar proliferation between TECs treated with or without
TGF-. Furthermore, increased expression of PCNA,
TGF-, and p-AKT and decreased expression of p21 and
p27 by proliferating TECs correlated with the proliferative
state of TECs in vivo. The results suggest that TGF-
promotes TEC proliferation in IFN-/ NOD.H-2h4 mice
by down-regulation of p21 and p27 via the AKT pathway.
The present study is unique in that, to our knowledge,
it is the first to demonstrate the pro-proliferative role of
TGF- on IFN-/ murine TECs. These results are con-
sistent with studies showing that TGF- can promote
proliferation of mesenchymal cells and fibroblasts35,36
and with studies showing that TGF- can promote prolif-
eration of goiter or thyroid tumor cells in vitro.37–39 TGF-
can also inhibit the growth of both rat and human
TECs11,40,41 through the Smad2/3 pathway. These ap-
parently contradictory findings may be explained, at least
in part, by differences in species and/or the concentra-
tion of TGF-. In recent years, several studies have dem-
onstrated that there are multiple TGF- signaling path-
ways, including both Smad and non-Smad pathways.
Which pathway is predominant after the binding of
TGF- to its receptors is determined by many factors,
including the cellular localization, phosphorylation
state, and expression levels of the postreceptor signal-
ing elements.1,42–46
The pro-proliferative role of TGF- was directly dem-
onstrated by using transgenic mice expressing the
dnTRII on their TECs. TECs from mice unable to re-
spond to TGF- did not proliferate in the presence of
TGF-, whereas TGF- consistently promoted prolifera-
tion of cultured TECs from Tg mice. On the other hand,
proliferation of TECs was significantly inhibited after ad-
dition of IFN- (Figures 2 and 3), whereas IFN- had no
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(Figures 2 and 3). Thus, TGF- and IFN- have contrast-
ing roles in TEC proliferation. This is consistent with stud-
ies in vivo showing that TGF- and IFN- reciprocally
regulate each other.15,16,21 Our previous studies have
shown that NOD.H-2h4 mice develop spontaneous auto-
immune thyroiditis characterized by lymphocyte infiltra-
tion of the thyroid. IFN-/NOD.H-2h4 mice do not de-
velop spontaneous autoimmune thyroiditis, but develop
severe TEC H/P with production of TGF- by proliferating
TECs. This suggests that the pro-proliferative effect of
TGF- is enhanced when IFN- is absent. The contrast-
ing roles of TGF- and IFN- in TEC proliferation in vitro
demonstrated in the present study thus provide direct
support for our hypothesis.
TGF- makes use of many intracellular signaling path-
ways in addition to Smads to regulate cellular functions,
including proliferation.1–4 The AKT pathway is one of the
most important non-Smad pathways considered to pro-mote cell proliferation.47,48 Mechanistically, this has been
linked to the ability of AKT to inhibit expression of the
cyclin-dependent kinase inhibitor p27, resulting in cell
cycle progression.49,50 In the present study, TGF--in-
duced proliferation of TECs was associated with in-
creased p-AKT and decreased p21 and p27 in cultured
TECs. AKT inhibitor reverses the down-regulation effect
of TGF- on p21 and p27, abolishing TGF--induced
proliferation of TECs. Thus, TGF- may promote TEC
proliferation by down-regulation of p21 and p27 via the
AKT pathway. These findings are consistent with studies
using other tissues.49,50 This hypothesis is also sup-
ported by in vivo results (Figure 7). In our TEC H/P transfer
model, increased proliferation of TECs 28 days after cell
transfer correlated with increased expression of TGF-
and p-AKT and decreased expression of p21 and p27 by
TECs in vivo. (We are currently designing further in vivo
studies to investigate whether AKT inhibitor can prevent
Figure 7. Increased proliferation of TECs corre-
lates with increased expression of TGF- and
p-AKT and decreased expression of P21 and P27
by TECs in vivo. Splenocytes from IFN-/ do-
nors with 5 TEC H/P severity scores were cul-
tured with mouse thyroglobulin and were trans-
ferred to SCID recipient mice. A: Results of H&E
staining and IHC staining for PCNA, TGF-, p-
AKT, p21, and p27 in thyroids at 28 and 60 days
after cell transfer. Original magnification, 400.
B–D: PCNA cells (red) or relative staining in-
tensity in five to six randomly selected high-
power fields of three slides/group were counted
or analyzed using MetaMorph software. Summa-
rized results are shown. *P  0.05 versus day 28.
E: Protein expression levels of p-AKT, p21, and
p27 evaluated by Western blot. *P  0.05 versus
day 28. Results shown are representative of two
or three independent experiments.or treat TEC H/P in this cell transfer model.) Notably, p21
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cytoplasm in TECs (Figure 7). Further studies are needed
to address the significance of cytoplasmic p21 and p27
in our vivo TEC H/P transfer model. Although the present
study demonstrated the involvement of the AKT pathway
in TEC proliferation induced by TGF-, other pathways or
mechanisms might also contribute to the pro-proliferative
effect of TGF- on TECs. Given that thyroid proliferation
and hyperplasia constitute one of the pathological fea-
tures in human thyroid diseases such as Graves’ disease
and thyroid adenoma and carcinoma,20 and given that
TGF- has been detected in these lesions,38,39,51 the
present findings might, at least in part, provide an expla-
nation for the mechanisms by which hyperplasia devel-
ops in these diseases.
In our animal model, anti-TGF- decreased TEC H/P
severity in SCID recipients of IFN-/ splenocytes,31
and transgenic overexpression of TGF- on TECs pro-
moted development of TEC H/P,52 suggesting a critical
role for TGF- in TEC H/P. TNF- also promotes TEC
proliferation in vitro and anti-TNF- also decreases TEC
H/P severity in SCID recipients of IFN-/ spleno-
cytes.31 The balance between pro- and antiproliferative
cytokines that use different signaling pathways and/or
crosstalk with each other can influence the balance be-
tween pro- and antiproliferative molecules to direct the
development of TEC H/P.
In summary, TGF- promotes proliferation of thyroid
epithelial cells in IFN-/mice, at least in part, by down-
regulation of p21 and p27 via the AKT pathway. Our
results highlight a critical role of the AKT pathway in TEC
proliferation and hyperplasia. These findings could con-
tribute to development of effective therapeutic strategies
targeting both the TGF- and AKT pathways for treatment
of hyperplasia and abnormal cell proliferation.
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